Bolt Biotherapeutics, Inc.
Clinical trials sponsored by Bolt Biotherapeutics, Inc., explained in plain language.
-
New breast cancer drug trial halted early after only 11 patients
Disease control TerminatedThis study tested a new drug called BDC-1001, alone or with another drug (pertuzumab), in people with advanced HER2-positive breast cancer who had already tried other treatments including trastuzumab deruxtecan. The goal was to see if the drug could shrink tumors. However, the st…
Phase: PHASE2 • Sponsor: Bolt Biotherapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 09:00 UTC
-
New hope for HER2 cancers? trial of BDC-1001 ends early
Disease control TerminatedThis study tested a new drug called BDC-1001, alone or with another drug (nivolumab), in people with advanced HER2-positive solid tumors (like breast, colorectal, or stomach cancer). The goal was to see if it was safe and could shrink tumors. The trial was stopped early, so resul…
Phase: PHASE1, PHASE2 • Sponsor: Bolt Biotherapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 08:59 UTC
-
Experimental cancer drug trial halted early
Disease control TerminatedThis early-stage study tested a new drug called BDC-3042, alone or with another drug (cemiplimab), in people with advanced solid tumors like breast, kidney, ovarian, head and neck, colorectal, lung cancer, or melanoma. The goal was to check safety and see if tumors shrank. The st…
Phase: PHASE1 • Sponsor: Bolt Biotherapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 08:56 UTC